Mitoxantrone treatment in advanced breast cancer.


Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy. In searching for an effective drug with low toxicity, many new drugs have been investigated. Seventeen patients with advanced breast cancer were treated with mitoxantrone, an analogue of adriamycin. The response rate was 44% (CR 6% + PR 38%). Side effects were fewer than those normally anticipated for most cytotoxic chemotherapy in that only two patients suffered hair loss and three nausea and vomiting. There was, however, significant bone marrow depression with granulocytopenia and two patients died of septicaemia following treatment. Cardiac toxicity occurred in two patients: of these, both had prior treatment with adriamycin, and one had prior radiotherapy to the chest wall. Both of these patients died.


Citations per Year

313 Citations

Semantic Scholar estimates that this publication has 313 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Leyden1984MitoxantroneTI, title={Mitoxantrone treatment in advanced breast cancer.}, author={Mark Leyden and Z. M. Cheng and John P. Collins and Ian S. Russell and Jane Andrews and Jesse R Sullivan}, journal={The Australian and New Zealand journal of surgery}, year={1984}, volume={54 1}, pages={21-4} }